TG Therapeutics

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

TG Therapeutics secures FDA approval for BRIUMVI, poised for growth

TG Therapeutics' Q4 2022 performance reflects a solid financial position with a focus on efficient capital management and commercial execution.
Strengths lie in FDA approval for BRIUMVI, positive launch progress, and commitment to supporting the MS community, positioning the company for growth.
Challenges include sustaining momentum, achieving broad payer coverage, managing expenses, and navigating complexities related to clinical trials.
Opportunities exist in further data analysis, market expansion, community engagement, and strategic investments, driving future growth and differentiation.

TG Therapeutics excels with BRIUMVI launch, eyes European expansion

TG Therapeutics demonstrated strong financial stability and strategic expense management in Q1 2023, despite reporting a net loss, showcasing resilience and efficient operations.
BRIUMVI's early success in the US market, positive feedback from healthcare providers, and progress in payer coverage position the product as a competitive and promising offering in the MS treatment class.
While facing decisions on international expansion and expense optimization, TG Therapeutics remains committed to serving the MS community and improving patient outcomes with BRIUMVI.
The company's focus on market access, product efficacy, and financial prudence sets a solid foundation for future growth and success in the competitive pharmaceutical landscape.

TG Therapeutics reports stellar Q2 performance and eyes global expansion

TG Therapeutics showcased robust financial performance and market acceptance of Briumvi in Q2 2023.
While facing challenges like revenue lag and potential market competition, the company remains well-positioned.
Opportunities lie in expanding market reach, product offerings, and maximizing the potential of Briumvi.
Overall, TG Therapeutics' strategic partnerships and positive market feedback position it for continued success.

TG Therapeutics excels in Q3 with BRIUMVI's market success

TG Therapeutics had a strong Q3 performance, driven by BRIUMVI's success and revenue exceeding expectations. The company is well-positioned with a healthy cash reserve and plans for market expansion. Challenges include potential competition from BTK drugs and seasonal market fluctuations.

TG Therapeutics excels in Q4 with BRIUMVI, eyes strong growth

TG Therapeutics demonstrated robust financial performance and strategic growth plans during the Q4 2023 earnings call, driven by the successful launch of BRIUMVI.
While facing challenges such as optimizing the infusion process and managing expenses, the company's focus on innovation and market expansion positions it for future success.
With a strong emphasis on commercialization, patent protection, and revenue targets, TG Therapeutics shows promising potential for sustained growth and value creation.

TG Therapeutics reports robust Q1 results, eyes growth opportunities

TG Therapeutics' Q1 performance reflects strong revenue growth driven by Briumvi's success and strategic investments in awareness and commercialization.
While facing challenges in market share growth and profitability, the company's focus on innovation and partnerships positions it well for future opportunities.
Maintaining a healthy financial position and a commitment to R&D underscore TG Therapeutics' resilience and potential for continued growth in the autoimmune therapy space.

TG Therapeutics excels in Q2, raises guidance and focuses on growth

TG Therapeutics delivered a strong Q2 performance with notable achievements in sales, R&D, and financial stability. While facing challenges related to internal controls and VA contract impact, the company is well-positioned to capitalize on opportunities for growth through market expansion and strategic initiatives.

TG Therapeutics reports robust Q3 earnings and outlines growth strategies

TG Therapeutics (TGTX) delivered a strong performance in Q3 2024, driven by the success of BRIUMVI and strategic growth initiatives.
While facing challenges in market competition and product development, TGTX remains focused on innovation, expansion, and maximizing shareholder value.
The company's financial strength, successful partnerships, and clear growth strategies position TGTX for continued success and future growth in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021 Fireside chat scheduled for 10:40 AM ET on Monday, September 27, 2021

TG Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held today, September 20, 2021 at 8:30 AM ET

TG Therapeutics Announces Combination Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

TG recently posted its 2Q2021 earnings report which shows interesting fundamental developments. It seemed that the market overreacted by significantly discounting the stock by over 20%. Despite modest sales in the early launch, you can expect stronger sales traction in the next few quarters.

TG Therapeutics: Amid Market Overreaction Is An Opportunity

Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET Investor & Analyst Virtual Event to Discuss Phase 1 U2 + Venetoclax Data to be held Monday, September 20, 2021 at 8:30 AM ET

TG Therapeutics Recaps Schedule of Upcoming Data Presentations at the XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021 Fireside chat available for on demand download at 7:00 AM ET on Monday, September 13, 2021

TG Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of four data presentations at the upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL), being held virtually September 17 – 20, 2021. Details of the data presentations are included below.

TG Therapeutics Announces Data Presentations at the Upcoming XIX International Workshop on Chronic Lymphocytic Leukemia (iwCLL)

Investors need to pay close attention to for TG Therapeutics (TGTX) stock based on the movements in the options market lately.

Do Options Traders Know Something About TG Therapeutics (TGTX) Stock We Don't?

AbCellera Biologics

ACADIA Pharma

Amicus Therapeutics

Sarepta Therapeutics

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its price target.

Why TG Therapeutics Shares Are Trading Lower Today

TG Therapeutics, Inc. (TGTX) CEO Mike Weiss on Q2 2021 Results - Earnings Call Transcript

H.C. Wainwright has lowered TG Therapeutics Inc's (NASDAQ:TGTX) price target to $84 from $89 and keeps a Buy rating on the stock.  Analyst Edward White mentioned that Ukoniq (umbralisib) revenue of $1.5 million was lower than expected in Q2.

TG Therapeutics Stock Plunged As H.C. Wainwright Cuts Target Price After Disappointing Q2

A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs.

Here's Why TG Therapeutics Stock Is Getting Hammered Today

TG Therapeutics (TGTX) delivered earnings and revenue surprises of -22.92% and -58.10%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

TG Therapeutics (TGTX) Reports Q2 Loss, Misses Revenue Estimates

Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET Conference call to be held today, Monday, August 2, 2021 at 8:30 AM ET

TG Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results

Ambarella

Alpha Metallurgical Resources

Keep an eye on stocks like TG Therapeutics (TGTX), Alpha Metallurgical Resources (AMR) & Ambarella (AMBA) for stellar earnings acceleration at the moment.

3 Stocks to Watch Out For Solid Earnings Acceleration

Conference call to be held Monday, August 2, 2021 at 8:30 AM ET Conference call to be held Monday, August 2, 2021 at 8:30 AM ET

TG Therapeutics to Host Conference Call on Second Quarter 2021 Financial Results and Business Update

TGTX has an approved product, an emerging revenue stream, and multiple catalysts. The cash position is strong, too.

TG Therapeutics: Continuing To Deliver

Fireside chat scheduled for Wednesday, July 14, 2021 at 12:30 PM ET Fireside chat scheduled for Wednesday, July 14, 2021 at 12:30 PM ET

TG Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

eXp World Holdings Inc

Ideaya Biosciences Inc

iQIYI

Seres Therapeutics

Mitek Systems

Moderna

Plug Power

Poshmark

Riot Blockchain

Twist Bioscience Corp

Vuzix

These July selections are the current top positive and negative forensic stocks based on combined scores from four different forensic algorithms. The past 5 Negative Forensic portfolios have returned: Jan 2021 +16.7%, July 2020: +114.1%, Feb 2020: +64.9%, Dec 2019: +59.0%, Oct 2019: +108.2%.

Forensic Value Stock Selections: Top Positive And Negative Scoring Stocks For Mid-Year 2021

DocuSign

Kaiser Aluminum

United Insurance Hlds

Western Digital

Western Digital (WDC), DocuSign (DOCU) & Kaiser Aluminum (KALU) are some of the stocks that at present are showing superb earnings acceleration, which may lead to an uptick in the stock price.

5 Stocks to Watch Out For Remarkable Earnings Acceleration

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II global, active controlled, Phase 3 trials evaluating ublituximab, the Company's investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide, in patients with relapsing forms of multiple sclerosis (RMS), during the 7th Congress of the European Academy of Neurology (EAN). This data was previously presented at the American Academy of Neurology (AAN) 73rd Annual Meeting.

TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at 7th Congress of the European Academy of Neurology

NEW YORK, June 18, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from two presentations evaluating TG-1701, the Company's investigational once-daily, oral BTK inhibitor, presented today during the 16th International Congress on Malignant Lymphoma (ICML). One presentation evaluated TG-1701 preclinically and the other included Phase 1 data evaluating TG-1701 as a monotherapy and as a triple therapy in combination with ublituximab, the Company's novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ® (umbralisib), the Company's once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The Phase 1 data presented today were previously presented at the 2021 American Society of Clinical Oncology (ASCO) annual meeting and the 2021 European Hematology Association annual meeting.

TG Therapeutics Announces Preclinical and Clinical Data Evaluating TG-1701 at the 16th International Congress on Malignant Lymphoma

NEW YORK, June 11, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company's investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab, the Company's novel glycoengineered anti-CD20 monoclonal antibody, and UKONIQ® (umbralisib), the Company's once-daily, inhibitor of PI3K-delta and CK1-epsilon in patients with front line or relapsed/refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Data from this trial were made available on demand this morning during the 3032 European Hematology Association (EHA) Virtual Congress. The data presented today were previously presented at the American Society of Clinical Oncology (ASCO) annual meeting.

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 European Hematology Association Virtual Congress

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations at the 16th International Congress on Malignant Lymphoma (ICML), being held virtually June 18 – 22, 2021. Details of the data presentations are included below.

TG Therapeutics Announces Data Presentations at the Upcoming 16th International Congress on Malignant Lymphoma

100% ORR in CLL patients treated with 300 mg QD of TG-1701 monotherapy (n=19)

TG Therapeutics Announces Data from a Phase 1 Study Evaluating TG-1701 as a Monotherapy and as a Triple Combination with Ublituximab and UKONIQ® at the 2021 American Society of Clinical Oncology Annual Meeting

News for TG Therapeutics Stock (TGTX)